Company intelligence / Profile preview

Zivena

Ownership: Private
Development stage: Commercial

Overview

Zivena has completed a Phase I dose-finding study for its lead product, Resmycin (doxorubicin HCl inhalation solution), targeting lung metastases from soft tissue sarcoma. The company is advancing to Phase II trials in non-small cell lung cancer patients. No published efficacy or safety data are available yet beyond this status update.

Therapeutic areas: Oncology
Modalities: Small moleculeChemotherapy agent
Industry: Biotech

Drug pipeline

1 asset

Inhaled doxorubicin

Discontinued

Beyond the preview

Go deeper on Zivena.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zivena.

Explore the full profile